Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]
Eligible age
18–65 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase II Investigator-Initiated Study to understand the vaccinal effect of HBsAg monoclonal Ab VIR-3434 in chronic hepatitis B infection. The purpose of this study is to test VIR-3434, an experimental drug that specifically targets the HBsAg of hepatitis B virus, to clear it from the body. This is an open label study and there is no placebo used in this study. All participants will receive the VIR-3434 for 48 weeks and then follow up in the study for 48 weeks. A total duration of approximately 104 weeks including screening period for the entire study.
Sponsor: University Health Network, Toronto
You may qualify if…
- ✓ 1. Age ≥ 18 to ≤65 years
- ✓ 2. Chronic HBV infection with evidence of HBsAg-positivity x \> 6 months
- ✓ 3. Quantitative HBsAg 300 - 10,000 IU/mL
- ✓ 4. On stable nucleos(t)ide therapy \>1 year
- ✓ 5. HBV DNA \< 60 IU/mL on 2 occasions at least 12 weeks apart
- ✓ 6. ALT ≤ 45 U/L on 2 occasions at least 12 weeks apart
- ✓ 7. Female subjects must have a negative pregnancy test or confirmation of postmenopausal status. Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and on Day 1, cannot be breast feeding, and must be willing to use highly effective methods of contraception 14 days before study drug administration through the study participation. Female subjects must also agree to refrain from egg donation and in vitro fertilization from the time of study drug administration through the study participation.
- ✓ 8. Male subjects with female partners of child-bearing potential must agree to meet 1 of the following contraception requirements from the time of study drug administration through the study participation: documentation of vasectomy or azoospermia, or male condom use plus partner use of 1 of the contraceptive options listed for contraception for WOCBP. Male subjects must also agree to not donate sperm from the time of study drug administration through the study participation.
You may not qualify if…
- ✕ 1. History of cirrhosis as evidenced by prior Liver Elastography (Fibroscan) \> 12 kilopascals (kPa), liver biopsy (F4 by METAVIR) or clinical evidence of decompensation (ascites, hepatic encephalopathy)
- ✕ 2. History of or current hepatocellular carcinoma
- ✕ 3. Hepatitis C Virus (HCV) RNA or anti-Hepatitis D Virus (HDV) positive
- ✕ 4. HIV co-infection
- ✕ 5. Pregnancy or lactation
- ✕ 6. Alanine Aminotransferase (ALT) \> 45 U/L
- ✕ 7. History of chronic liver disease other than HBV aside from fatty liver documented only on US
- ✕ 8. Use of peginterferon therapy for HBV infection within past 12 months
Source: ClinicalTrials.gov · NCT06216470 · last updated 2025-05-29